Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GYRE 
Gyre Therapeutics Inc. (GYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: GYRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18
1 Year Target Price $18
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.54% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 746.58M USD | Price to earnings Ratio 193.75 | 1Y Target Price 18 |
Price to earnings Ratio 193.75 | 1Y Target Price 18 | ||
Volume (30-day avg) 1 | Beta 7.11 | 52 Weeks Range 6.11 - 14.42 | Updated Date 11/30/2025 |
52 Weeks Range 6.11 - 14.42 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-12 | When - | Estimate 0.07 | Actual 0.03 |
Profitability
Profit Margin 6.2% | Operating Margin (TTM) 22.66% |
Management Effectiveness
Return on Assets (TTM) 5.28% | Return on Equity (TTM) 10.02% |
Valuation
Trailing PE 193.75 | Forward PE 77.52 | Enterprise Value 687697966 | Price to Sales(TTM) 6.96 |
Enterprise Value 687697966 | Price to Sales(TTM) 6.96 | ||
Enterprise Value to Revenue 6.41 | Enterprise Value to EBITDA 47.89 | Shares Outstanding 96333157 | Shares Floating 20523048 |
Shares Outstanding 96333157 | Shares Floating 20523048 | ||
Percent Insiders 87.1 | Percent Institutions 3.43 |
Upturn AI SWOT
Gyre Therapeutics Inc.
Company Overview
History and Background
Gyre Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for liver diseases. Founded in 2017, Gyre is based in San Diego, CA. They've focused on oligonucleotide-based therapies targeting specific liver diseases.
Core Business Areas
- Drug Development: Research and development of novel therapeutic candidates for liver diseases, including NASH and liver fibrosis.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
- Partnerships and Licensing: Establishing partnerships with other pharmaceutical companies or licensing their technologies.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure is typical of a clinical-stage biotech company, with departments dedicated to research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- GYR-531: GYR-531 is Gyre Therapeutics' lead drug candidate for the treatment of non-alcoholic steatohepatitis (NASH). Data on market share, number of users, or revenue is unavailable as the product is still in clinical trials. Competitors include Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. The liver disease market, particularly NASH, is large and rapidly growing due to the increasing prevalence of obesity and diabetes.
Positioning
Gyre Therapeutics is positioned as an innovative company focusing on novel therapies for liver diseases. Their competitive advantage lies in their specific therapeutic targets and oligonucleotide-based technology.
Total Addressable Market (TAM)
The NASH market is expected to reach $50 billion by 2030. Gyre Therapeutics is positioned to capture a portion of this market if GYR-531 is approved. The current valuation does not fully reflect the TAM potential.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Oligonucleotide-based technology
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
- Single lead drug candidate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other liver diseases
- Positive clinical trial results
- FDA approval of GYR-531
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies
- Patent challenges
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
- ICPT
Competitive Landscape
Gyre Therapeutics faces significant competition from larger, more established pharmaceutical companies. Their advantage lies in their novel approach, but they face risks related to clinical trial success and funding.
Growth Trajectory and Initiatives
Historical Growth: N/A (pre-revenue stage)
Future Projections: Future growth is dependent on the successful development and commercialization of their drug candidates. Analyst estimates are unavailable.
Recent Initiatives: Focusing on advancing GYR-531 through clinical trials and exploring potential partnerships.
Summary
Gyre Therapeutics is a high-risk, high-reward clinical-stage biopharmaceutical company focused on liver diseases. The company's success hinges on the positive outcomes of clinical trials for GYR-531. Strong intellectual property and an experienced team are positives, but limited financial resources and reliance on a single lead candidate present challenges. They need to secure funding and prove their product works.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gyre Therapeutics Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2006-04-12 | Interim CEO & Executive Chair Mr. Ping Zhang | ||
Sector Healthcare | Industry Biotechnology | Full time employees 579 | Website https://www.gyretx.com |
Full time employees 579 | Website https://www.gyretx.com | ||
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.